These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 34937906)
21. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening. Koole C; Wootten D; Simms J; Valant C; Sridhar R; Woodman OL; Miller LJ; Summers RJ; Christopoulos A; Sexton PM Mol Pharmacol; 2010 Sep; 78(3):456-65. PubMed ID: 20547734 [TBL] [Abstract][Full Text] [Related]
22. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. Montrose-Rafizadeh C; Yang H; Rodgers BD; Beday A; Pritchette LA; Eng J J Biol Chem; 1997 Aug; 272(34):21201-6. PubMed ID: 9261127 [TBL] [Abstract][Full Text] [Related]
23. Differential Requirement of the Extracellular Domain in Activation of Class B G Protein-coupled Receptors. Zhao LH; Yin Y; Yang D; Liu B; Hou L; Wang X; Pal K; Jiang Y; Feng Y; Cai X; Dai A; Liu M; Wang MW; Melcher K; Xu HE J Biol Chem; 2016 Jul; 291(29):15119-30. PubMed ID: 27226600 [TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain. West GM; Willard FS; Sloop KW; Showalter AD; Pascal BD; Griffin PR PLoS One; 2014; 9(9):e105683. PubMed ID: 25180755 [TBL] [Abstract][Full Text] [Related]
25. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Rieg T; Gerasimova M; Murray F; Masuda T; Tang T; Rose M; Drucker DJ; Vallon V Am J Physiol Renal Physiol; 2012 Oct; 303(7):F963-71. PubMed ID: 22832924 [TBL] [Abstract][Full Text] [Related]
26. The G Protein-First Mechanism for Activation of the Class B Glucagon-like Peptide 1 Receptor Coupled to N-Terminal Domain-Mediated Conformational Progression. Li B; Yang MY; Kim SK; Goddard WA J Am Chem Soc; 2024 Sep; 146(38):26251-26260. PubMed ID: 39266057 [TBL] [Abstract][Full Text] [Related]
27. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors. Dickson SL; Shirazi RH; Hansson C; Bergquist F; Nissbrandt H; Skibicka KP J Neurosci; 2012 Apr; 32(14):4812-20. PubMed ID: 22492036 [TBL] [Abstract][Full Text] [Related]
28. Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents. Vallöf D; Kalafateli AL; Jerlhag E Psychoneuroendocrinology; 2019 May; 103():284-295. PubMed ID: 30771711 [TBL] [Abstract][Full Text] [Related]
29. Activation of Glucagon-Like Peptide-1 Receptor Promotes Neuroprotection in Experimental Autoimmune Encephalomyelitis by Reducing Neuroinflammatory Responses. Lee CH; Jeon SJ; Cho KS; Moon E; Sapkota A; Jun HS; Ryu JH; Choi JW Mol Neurobiol; 2018 Apr; 55(4):3007-3020. PubMed ID: 28456941 [TBL] [Abstract][Full Text] [Related]
30. Nonconventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP. Chepurny OG; Matsoukas MT; Liapakis G; Leech CA; Milliken BT; Doyle RP; Holz GG J Biol Chem; 2019 Mar; 294(10):3514-3531. PubMed ID: 30622136 [TBL] [Abstract][Full Text] [Related]
31. Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism. Lei S; Clydesdale L; Dai A; Cai X; Feng Y; Yang D; Liang YL; Koole C; Zhao P; Coudrat T; Christopoulos A; Wang MW; Wootten D; Sexton PM J Biol Chem; 2018 Jun; 293(24):9370-9387. PubMed ID: 29717000 [TBL] [Abstract][Full Text] [Related]
32. Influence of Trp-Cage on the Function and Stability of GLP-1R Agonist Exenatide Derivatives. Horváth D; Stráner P; Taricska N; Fazekas Z; Menyhárd DK; Perczel A J Med Chem; 2024 Sep; 67(18):16757-16772. PubMed ID: 39254428 [TBL] [Abstract][Full Text] [Related]
33. Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists. Evers A; Haack T; Lorenz M; Bossart M; Elvert R; Henkel B; Stengelin S; Kurz M; Glien M; Dudda A; Lorenz K; Kadereit D; Wagner M J Med Chem; 2017 May; 60(10):4293-4303. PubMed ID: 28448133 [TBL] [Abstract][Full Text] [Related]
34. Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects. Murakami T; Fujimoto H; Fujita N; Hamamatsu K; Yabe D; Inagaki N J Diabetes Investig; 2020 Nov; 11(6):1448-1456. PubMed ID: 32323451 [TBL] [Abstract][Full Text] [Related]
35. Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists. Zhang X; Belousoff MJ; Zhao P; Kooistra AJ; Truong TT; Ang SY; Underwood CR; Egebjerg T; Šenel P; Stewart GD; Liang YL; Glukhova A; Venugopal H; Christopoulos A; Furness SGB; Miller LJ; Reedtz-Runge S; Langmead CJ; Gloriam DE; Danev R; Sexton PM; Wootten D Mol Cell; 2020 Nov; 80(3):485-500.e7. PubMed ID: 33027691 [TBL] [Abstract][Full Text] [Related]